ModifiedUnitedHealthcarePolicy CSIS1NJ.K

Carrier Testing Panels for Genetic Diseases (for New Jersey Only)

Defines medical policy for carrier genetic testing panels used in reproductive carrier screening for members in New Jersey, including coverage rationale, recommended panel sizes, and testing contexts.

Policy Summary

PayerUnitedHealthcare

PolicyCarrier Testing Panels for Genetic Diseases (for New Jersey Only)

Policy CodePolicy CSIS1NJ.K

Change TypeDefinitions and code notation updated

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionVerify member benefits and state Medicaid coverage before ordering tests; CPT 81412 may not be covered by New Jersey Medicaid.

SourceLink

POLICY UPDATE CHANGES

Definitions updated for 'Gene Panel' and CPT code 81412 noted as not on the State of New Jersey Medicaid Fee Schedule.

Supporting clinical evidence, FDA, and references sections were updated to reflect current information.

up to 6 genespanels proven medically necessary (certain situations)

up to 15 genespanels proven medically necessary with specified criteria

16+ genespanels considered unproven and not medically necessary

NJpolicy application state

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Definitions and codes noted in 08/01/2025 revision

Coverage Criteria for Reproductive Carrier Screening Panels

inv-01: Medically Necessary Panel Criteria

Covered when ALL of the following panel-size provisions and attendant criteria are met:

Covered Panel Options: Reproductive carrier screening panels of up to six genespanel size

Panels of up to six genes are considered proven and medically necessary.

Covered up to 15 genes when criteria met

Qualifying criteria for coverage of up to 15-gene panels: A biological first- or second-degree relative is affected by one or more of the conditions evaluated by the panel; OR Ashkenazi Jewish ancestry (individual or reproductive partner has at least one parent or grandparent of Ashkenazi Jewish descent)clinical/family history

inv-02: Covered when following professional guidance

Coverage and offering considerations align with professional society guidance and tiered approaches; offer and counseling expectations include:

Core recommended screening: Offer carrier screening for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies to all individuals who are pregnant or considering pregnancy; if hemoglobinopathy testing has not been performed, offer at the first prenatal visit or when planning pregnancy.

Based on ACOG Committee Opinions and Practice Advisory

Expanded / tiered screening options: Offer expanded carrier screening (ECS) or ACMG Tier 3 screening broadly to pregnant patients and those planning pregnancy; reserve Tier 4 screening for consanguinity (second cousins or closer) or when family/personal medical history warrants it.ACMG tier thresholds

ACMG recommends an ethnic/population-neutral, tiered approach; NSGC issues a conditional recommendation to offer ECS to individuals considering reproduction.

Counseling and shared decision-making: Provide pre-test genetic counseling and support shared decision-making that considers individual values and preferences prior to carrier screening.

NSGC conditional recommendation and ACOG emphasis on counseling

Reproductive carrier screening panels composed of 16 or more genes are considered unproven and not medically necessary. In addition, carrier screening for indications other than those specifically described as covered in this policy (e.g., routine population screening outside the stated indications) is considered unproven and not medically necessary. This stance aligns with the policy statement that panels up to six genes are proven and medically necessary, and up to 15 genes may be medically necessary when specified clinical or family-history criteria are met.

Available studies evaluating expanded or pan-ethnic carrier screening demonstrate methodological inconsistency and important limitations. Most published studies are observational, many were rated poor or very poor quality with high risk of bias, and study populations and laboratory methods varied substantially across reports. Differences in which genes or platforms were tested, variable definitions of detection rate and recurrence risk, and disparate sampling limit the ability to generalize outcomes and to quantify the comparative clinical impact of broad ECS versus guideline-based screening.

The Royal College of Obstetricians and Gynaecologists (RCOG) states there is insufficient evidence to recommend testing all individuals with some expanded carrier screening (ECS) panels. RCOG recommends that providers understand the specific genes and composition of any ECS panel used and that results be interpreted by clinicians with appropriate genetics expertise; the report also highlights the need for additional work to define appropriate gene inclusion for ECS panels.

This policy reiterates that reproductive carrier screening panels composed of 16 or more genes are unproven and not medically necessary. Likewise, carrier screening performed for indications not described as covered in this policy is considered unproven and not medically necessary. The policy notes that panels of up to six genes are proven and medically necessary, and panels of up to 15 genes may be covered when the specified family-history or ancestry criteria are met.

Key evidence gaps remain and limit broad adoption of expanded carrier screening. Prospective, comparative studies that directly compare current guideline- or ethnicity-based screening to ECS are needed. Existing analyses often rely on modeled frequency estimates and referred populations that may not reflect general reproductive populations; admixture, variable sampling, and differing laboratory methods further constrain generalizability and the ability to establish clinical utility for broad panels.

Indications Covered by Policy

inv-32: Reproductive carrier screening for individuals planning pregnancy or currently pregnant

Covered indications for reproductive carrier screening in individuals planning pregnancy or currently pregnant:

Standard reproductive carrier screening: Panels of up to six genes for reproductive carrier screening are considered medically necessary for individuals planning pregnancy or currently pregnant.panel size <= 6 genes

Note: It is strongly recommended that panels include screening for cystic fibrosis (CFTR) and spinal muscular atrophy (SMN1).

Expanded coverage with qualifying criteria

Qualifying criteria (apply to individual or reproductive partner): A biological first- or second-degree relative affected by one or more of the conditions evaluated by the panel; OR Ashkenazi Jewish ancestry (at least one parent or grandparent of Ashkenazi Jewish descent)clinical/family history or ancestry

Eligibility Requirements for Covered Testing

Several studies compared expanded carrier screening to guideline-based or ethnicity-based approaches; prior guideline-recommended tests (for example, cystic fibrosis and other condition-focused panels such as Ashkenazi Jewish screening) were commonly used as comparators. Published analyses demonstrate that laboratory selection of platforms and gene lists varied, and some studies showed that broader panels can identify pathogenic variants not captured by traditional targeted screening approaches.

Applicable Codes and Coding Notes

Applicable CPT/PLA codes (reference)CPT

0400U	Obstetrics (expanded carrier screening), 145 genes by next generation sequencing; fragment analysis and multiplex ligation dependent probe amplification, DNA, reported as carrier positive or negative.
81412	Ashkenazi Jewish associated disorders genomic sequence analysis panel, must include sequencing of at least 9 genes (ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, SMPD1).
81443	Genetic testing for severe inherited conditions genomic sequence analysis panel, must include sequencing of at least 15 genes (examples listed).
81479	Unlisted molecular pathology procedure.

Applicable Codes and State-Specific NotesCPT

81412

Notation added that CPT code 81412 is not on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered by the State of New Jersey Medicaid Program

Carrier frequency thresholds for panel inclusion — ACOG/ACMG guidance

ACOG recommended frequencyTarget conditions with carrier frequency >= 1/100 (correlates with disease incidence ~1/40,000)

ACMG practice resource (Tier basis)Recommends tier-based system and includes Tier 3 screening for conditions with carrier frequency >= 1/200 plus CF and SMA

Panel design implicationConservative panels using ~1/100 include ~37 conditions; more liberal ~1/200 panels include ~74 conditions (per Johansen Taber et al.)

Carrier frequency thresholds (ACMG tiers) — tier definitions and thresholds

Tier 2 definitionTier 2: carrier frequency >= 1/100 (includes Tier 1)

Tier 3 definition

Provider Actions, Documentation, and Billing Considerations

Documentation Required

Genetic counseling documentation

Pre-test genetic counseling is strongly recommended. Document that counseling was provided (date, counselor name/credentials, topics discussed including test limitations, possible results, and implications for the patient and partner) and retain records in the medical record.

Counseling time burden: prepare for significant counseling follow-up for positive or complex results (studies report median ~64 minutes preparation for follow-up visits).
Document patient informed consent for testing and that alternatives and limitations were discussed.
If testing is ordered during pregnancy, document time-sensitive counseling and any impacts on management.

Denial Risk

Implementation burden and panel-size considerations

Large multigene panels increase the likelihood of identifying carriers for rare or mild conditions and may create an implementation burden for clinical care (additional partner testing, referrals, and counseling). Consider panel size relative to clinical indication and available resources for follow-up.

Services Considered Not Medically Necessary

Reproductive carrier screening panels comprised of 16 or more genes and carrier screening for indications not described as covered are considered not medically necessary and may be denied. Coverage decisions for reproductive carrier screening are tiered by panel size and specific clinical or family-history criteria as described in the coverage criteria.

There is no broad consensus on which genes should be included in pan-ethnic panels. Many commercially available panels include genes with variable levels of supporting evidence or that are associated with mild or late-onset phenotypes, which raises concerns about the clinical utility and the potential burden of follow-up for findings of uncertain or limited clinical significance.

RCOG notes that evidence is insufficient to support universal testing with some ECS panels; this implies that certain broad panels may not be routinely recommended without clearer evidence of benefit, standardized gene inclusion criteria, and appropriate resources for interpretation and counseling.

Policy revisions effective 08/01/2025 include an operational notation that CPT code 81412 is not listed on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered by the New Jersey Medicaid Program. Providers should verify member-specific benefits and state Medicaid coverage when ordering tests billed with this code.

Definitions

Carrier screening identifies asymptomatic individuals who may carry genetic variants that could be passed to biological children. Next-generation sequencing (NGS) and other molecular methods have enabled multi-gene panels—ranging from targeted genotyping to large NGS-based panels—to be offered as pan-ethnic or ancestry-targeted screening. Professional guidance (for example, ACOG) recommends routine screening for cystic fibrosis and spinal muscular atrophy, and hemoglobinopathy testing in specified circumstances, and highlights the use of NGS-based panels as one approach to detect carriers when indicated.

Definition — Carrier Screening

DefinitionCarrier Screening: Genetic testing performed on an asymptomatic individual to determine whether they may have a genetic variant associated with a disorder that could be passed to biological children.

PurposeIdentify individuals or reproductive partners who are at risk of having a child with a genetic disorder

ContextIncludes pan-ethnic, ethnicity-based, or family-history-based panels; counseling is strongly recommended prior to testing

Definition — First-Degree Relative

Background and Supporting Evidence

Carrier screening is used to identify asymptomatic individuals who may carry variants that can be transmitted to offspring. Advances in NGS permit screening of multiple genes simultaneously, enabling pan-ethnic expanded carrier screening as well as ancestry-targeted panels. Professional society recommendations emphasize testing for conditions such as cystic fibrosis and spinal muscular atrophy and recommend genetic counseling to support informed decision-making before and after testing.

Evidence evaluating expanded carrier screening is limited by inconsistent study methodologies and variability across laboratories and populations. Observational designs, heterogeneous panels and platforms, and differing outcome definitions contribute to uncertainty about comparative effectiveness and generalizability; these limitations underscore the importance of following established guideline-based screening and ensuring appropriate counseling and specialist interpretation when expanded panels are used.

Policy Revision History

08/01/2025revisionLatest

Definitions updated (including 'Gene Panel'); notation added that CPT code 81412 is not on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered by NJ Medicaid; supporting sections (Clinical Evidence, FDA, References) updated.

Policy Summary

PayerUnitedHealthcare

PolicyCarrier Testing Panels for Genetic Diseases (for New Jersey Only)

Policy CodePolicy CSIS1NJ.K

Change TypeDefinitions and code notation updated

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionVerify member benefits and state Medicaid coverage before ordering tests; CPT 81412 may not be covered by New Jersey Medicaid.

SourceLink

On This Page

Recommended condition inclusion: Panels should include testing for cystic fibrosis (CFTR) and spinal muscular atrophy (SMN1); hemoglobinopathy testing should be offered per ACOG guidance.

ACOG recommends CF, SMA, and hemoglobinopathies be offered to all individuals considering or currently pregnant.

inv-33: Preconception or prenatal carrier screening to identify at-risk couples for AR and X-linked conditions

Covered when used to identify at-risk couples so they can pursue reproductive options:

Purpose of preconception/prenatal screening: Preconception or prenatal carrier screening is intended to identify at-risk couples for autosomal recessive and X-linked conditions to inform reproductive decision-making and options (for example, preimplantation genetic testing, prenatal diagnostic testing, or pregnancy planning).

Evidence shows preconception results more frequently lead to pursuit of reproductive options compared with results disclosed during pregnancy.

Timing impact on decisions: When results are obtained preconception, couples more often pursue interventions such as preimplantation genetic testing (PGT) or alternative reproductive planning; when results are disclosed during pregnancy, changes in reproductive plans are less frequent.

Findings summarized from systematic reviews and cohort surveys.

inv-34: Individuals who are pregnant or considering pregnancy and their partners

Covered when aligned with professional recommendations for common reproductive-impact conditions; broader ECS may be offered per guidance:

Core conditions for all individuals and partners: Offer carrier screening for cystic fibrosis (CF) and spinal muscular atrophy (SMA) to individuals who are pregnant or considering pregnancy and to their reproductive partners as appropriate; offer hemoglobinopathy testing to all individuals planning pregnancy or at the first prenatal visit if not previously tested.

ACOG Committee Opinions recommend offering CF, SMA, and hemoglobinopathy screening to all individuals considering or currently pregnant.

Broader ECS / Tier 3 considerations: Expanded carrier screening (ECS) or ACMG Tier 3 screening may be offered for reproductive risk assessment to individuals and their partners; Tier 4 panels should be reserved for consanguinity or when family/personal history indicates.ACMG tier thresholds

ACMG recommends Tier 3 be offered broadly; NSGC conditionally recommends offering ECS to all individuals considering reproduction.

Counseling requirement: Pre-test genetic counseling and appropriate follow-up resources should be provided due to potential complexity and downstream implications of ECS results.

Professional societies emphasize genetic counseling and shared decision-making.

Tier 3: carrier frequency >= 1/200 (includes Tier 2 and X-linked conditions); recommended to be offered to all pregnant patients and those planning pregnancy

Tier 4 definitionTier 4: carrier frequency 1/200 (includes Tier 3); reserved for consanguinity or specific family/personal medical history

Implementation burden risk: panels detecting many conditions can require substantial clinical follow-up and specialist referrals; assess practice capacity before ordering large panels.
Panel-size denial risk: reproductive carrier screening panels of 16 or more genes may be considered not medically necessary per policy; verify medical necessity for panels >15 genes.

Documentation Required

Ethnicity, ancestry, and family history

Self-reported ethnicity is unreliable for estimating genetic risk; document ancestry, family history, and, when available, genetic ancestry or objective markers. Use detailed family history rather than a single ethnic checkbox whenever possible.

Ethnicity and ancestry documentation: record detailed ancestry (country/region of origin, affected relatives) and family history to inform test selection and interpretation.
Note that admixed populations may have variable carrier risks; consider pan-ethnic or expanded approaches when ancestry is uncertain.

Note

Testing platform selection

Testing platform and gene content affect detection rates and downstream implications. Choose a platform and panel size appropriate to the clinical question and document the chosen platform in the order.

Testing platform selection: targeted genotyping vs NGS have different detection capabilities — NGS generally detects more variants and will increase positive/uncertain findings.
Specify genes requested and platform on the laboratory requisition; document rationale for expanded panels when used.

Prior Authorization

Verify coverage and prior authorization

Coverage and payment may vary by the member's specific plan and by state programs (e.g., New Jersey Medicaid). Verify member benefits and any prior authorization requirements before ordering.

Check plan-specific requirements: federal, state, or contractual requirements govern coverage when they differ from this policy.
CPT code note: CPT 81412 is listed in applicable codes but is not on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered for NJ Medicaid members — verify NJ Medicaid coverage separately.

Note

Providers should align ordering practices with available resources and payer requirements. Pre-test counseling, documentation of ancestry/family history, explicit selection of testing platform and gene content, and verification of member-specific coverage/prior authorization are recommended steps.

Pre-test genetic counseling strongly recommended and should be documented as noted above.
Confirm benefit coverage, PA requirements, and NJ Medicaid applicability (especially for CPT 81412) before ordering.
Consider limiting panel size to guideline-supported gene counts (up to 6 genes generally, up to 15 genes when criteria met) to reduce denial risk and implementation burden.

DefinitionFirst-Degree Relative: Parents, siblings, and children.

RelevancePresence of an affected first-degree relative can qualify an individual for expanded (up to 15-gene) panel coverage per policy criteria

SourceDefined per NCCN (2025) as cited in policy

Definition — Second-Degree Relative

DefinitionSecond-Degree Relative: Half-siblings, aunts, uncles, grandparents, grandchildren, and nieces/nephews.

RelevanceAn affected biological second-degree relative can meet criteria for up to 15-gene panel coverage

SourceDefined per NCCN (2025) as cited in policy

Disease severity classification for ECS

PurposeSeverity classification algorithm stratifies diseases into mild, moderate, severe, and profound for ECS panel inclusion and interpretation.

UseMapped disease traits to ACOG severity criteria; majority of genes screened met at least one severity criterion in the referenced study

ImplicationSeverity classification helps prioritize conditions for panel inclusion and counseling messages

Targeted genotyping vs NGS definition

Targeted genotypingTests a predefined set of known pathogenic variants (example: panels testing a set list of variants).

Next-generation sequencing (NGS)Sequences full genes and can detect additional carriers beyond known variant lists; used for expanded carrier screening panels screening many genes.

Practical differencePlatform choice affects detection rates and should be documented when ordering; laboratories may offer either approach

Pan-ethnic / Expanded Carrier Screening (ECS) definition

DefinitionPan-ethnic / Expanded Carrier Screening (ECS): Carrier screening panels offered irrespective of self-reported ethnicity that test multiple genes/variants (via targeted genotyping or NGS) to detect carriers of autosomal recessive and X-linked disorders.

RationaleRecommended because self-reported ethnicity is unreliable and ancestry determination may require genetic approaches; provides comprehensive risk assessment in diverse populations.

Panel composition noteThere is lack of standardization in panel composition; professional guidance recommends thresholds (e.g., ACOG >=1/100, ACMG tiered approach) to guide inclusion.

ACMG tiered screening definition

DefinitionACMG tiered screening: a tiered approach built on carrier frequency thresholds where tiers guide which conditions are broadly offered versus reserved for specific history or consanguinity.

OperationalizationTier 3 (>=1/200) is offered broadly to pregnant patients and those planning pregnancy; Tier 4 reserved for consanguinity or relevant family/personal history.

Additional guidanceACMG promotes ethnicity-neutral paradigms and replacing the term 'expanded carrier screening' with 'carrier screening' in practice.